Año: 2012
Journal Impact Factor (JIF): 6.4070
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
INFECTIOUS DISEASES | SCIE | 3/70 | Q1 | T1 | D1 |
IMMUNOLOGY | SCIE | 16/137 | Q1 | T1 | D2 |
VIROLOGY | SCIE | 4/34 | Q1 | T1 | D2 |
Año: 2017
Journal Citation Indicator (JCI): 1,370
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
IMMUNOLOGY | 24/173 | Q1 | T1 | D2 | 86,42 |
INFECTIOUS DISEASES | 11/111 | Q1 | T1 | D1 | 90,54 |
VIROLOGY | 5/39 | Q1 | T1 | D2 | 88,46 |
Año:
2012
CiteScore:
12,600
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
General Medicine | 129/3199 | Q1 | T1 | D1 |
Immunology | 16/179 | Q1 | T1 | D1 |
Immunology and Allergy | 12/161 | Q1 | T1 | D1 |
Infectious Diseases | 9/230 | Q1 | T1 | D1 |
SJR año:
2012
Factor de Impacto:
3,970
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Immunology | 18/208 | Q1 | T1 | D1 |
Immunology and Allergy | 13/186 | Q1 | T1 | D1 |
Infectious Diseases | 8/288 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
Abbott | - |
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY | R01HS018372 |
AHRQ grant | R01-HS018372 |
Boehringer-Ingelheim | - |
Bristol Myers Squibb | - |
Bristol-Myers-Squibb | - |
Gilead | - |
Gilead Sciences | - |
GlaxoSmithKline | - |
Janssen | - |
Janssen Pharmaceutica | - |
Medical Research Council | G0700820; G0900274; MR/J002380/1 |
Merck | - |
MRC | G0700820 |
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | R01HL090342; RC1HL100347; R01HL095136 |
National Institute for Health Research | NF-SI-0611-10168 |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | R01AI073127; R37AI032475 |
NATIONAL INSTITUTE OF MENTAL HEALTH | P30MH062294 |
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | U01AA020790; U10AA013566; U24AA020794 |
NIH | R01-AI073127; U10-AA013566; U10-AA13566; U24-AA020794; U01-AA020790; R01-HL095136; R01-HL090342; RCI-HL100347; U01-AI069918; P30-MH062294 |
Office of Academic Affiliations (Medical Informatics Fellowship) | - |
Roche | - |
Tibotec | - |
Veterans Health Administration Office of Research and Development | VA REA 08-266 |
ViiV Healthcare | - |
# | Autor |
---|---|
1 | |
# | Autoría grupal |
1 | López Cortés, Luis Fernando (HIV-CAUSAL Collaboration) |